PTGS2 and breast carcinoma: In the 1833 xenograft model of skeleton metastasis from breast carcinoma the concomitant exposure to miR-125b mimic and NS-398, a specific PTGS2 chemical inhibitor, reduced and delayed the outgrowth of osteolytic bone metastases prolonging mice survival in respect to the single treatments.